UCLA to receive $520M for selling rights to cancer drug

UCLA to receive $520M for selling rights to cancer drug

UCLA researchers created several compounds for prostate cancer treatment – the Xtandi compound was licensed to Medivation, but UCLA licensed another series of compounds to Aragon Pharmaceuticals, Inc. Medivation claimed it held the rights to those …

(Visited 1 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.